Telix Pharmaceuticals Ltd
TLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002007191
No open-market purchases or sales by Telix Pharmaceuticals Ltd insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $36.6M in total; no superinvestor holds it.
Other share classesTLPPF
13F holders, Q1 2025
Institutional positions in Telix Pharmaceuticals Ltd as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- +5 vs. Q4 2024
- Shares held
- 47.6K
- +43.9K (+1,177.4%) vs. Q4 2024
- Total value
- $798.6K
- +$741.1K (+1,290.2%) vs. Q4 2024
- New holders
- 5
- 0 more added
- Sold out
- 0
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 62 | $36.6M |
| Q1 2026 | 40 | $24.5M |
| Q4 2025 | 40 | $8.47M |
| Q3 2025 | 27 | $7.88M |
| Q2 2025 | 21 | $7.29M |
| Q1 2025 | 6 | $798.6K |
| Q4 2024 | 1 | $57.4K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Telix Pharmaceuticals Ltd; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Abc Arbitrage SA | 26,939 | $451.5K | 0.08% | +26,939 | New |
| Private Advisor Group, LLC | 10,140 | $169.9K | 0.00% | +10,140 | New |
| Morgan Stanley | 5,634 | $94.4K | 0.00% | +5,634 | New |
| UBS Group AG | 3,651 | $61.2K | 0.00% | −79−2.1% | Reduced |
| Rhumbline Advisers | 1,146 | $19.2K | 0.00% | +1,146 | New |
| EverSource Wealth Advisors, LLC | 137 | $2.30K | 0.00% | +137 | New |